Merck & Co., Inc.
corporate_fare Company Profile
Merck & Co., Inc. (NYSE:MRK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 53 items for MRK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MRK spans 10-Q, 8-K.
Recent high-impact activity:
- Inhibrx's INBRX-106 + Keytruda Nearly Doubles Response Rate in Head and Neck Cancer
- Novartis Inks $3.2B Deal for Alteogen's Drug Delivery Tech Used in Merck's Keytruda
- Senators Question Health Secretary Kennedy on Gardasil Settlement Disclosures
- Merck's mRNA Melanoma Vaccine Cuts Recurrence in Late-Stage Trial
- Merck-Moderna mRNA Cancer Therapy Hits Phase 3 Endpoints in Melanoma
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for MRK, detected from its recent SEC filings · based on capital-structure filings through 2026-05-20.
Debt Offering Finalized · Refinancing Acquisition Debt
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →